Preserved C-reactive protein responses to blood stream infections following tocilizumab treatment for COVID-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2021.07.03.21259949: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization Patient use of tocilizumab originated either through delivery of routine clinical care or from randomised clinical trials after unblinding. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources All analyses were performed using Microsoft Excel and GraphPad Prism. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: …SciScore for 10.1101/2021.07.03.21259949: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization Patient use of tocilizumab originated either through delivery of routine clinical care or from randomised clinical trials after unblinding. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources All analyses were performed using Microsoft Excel and GraphPad Prism. Microsoft Excelsuggested: (Microsoft Excel, RRID:SCR_016137)GraphPad Prismsuggested: (GraphPad Prism, RRID:SCR_002798)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Our study has limitations. The single-centre, retrospective source of our clinical data constrained numbers of patients that could be identified in each group, negating the ability to correct for potential confounders. Nevertheless, the increased frequency of corticosteroid use in patients with a BSI that had received tocilizumab may have attenuated CRP responses further, counter to our observations. BSIs provided a standardised, prototypic model for bacterial infections to compare across clinical groups, but limited extrapolation to non-BSI settings. Further studies of COVID-19 associated non-BSI bacterial co-infections will be needed to confirm the generalisability of our findings. In conclusion, we show that tocilizumab use in severe COVID-19 does not prevent elevations in CRP concentration following the onset of a confirmed bacterial co-infection, as modelled by BSIs. Use of tocilizumab should not negate judicious, CRP-guided use of antibiotics in COVID-19.
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
